相似文献
1
Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease.优特克单抗、维多珠单抗和托法替布在炎症性肠病中的治疗药物监测（TDM）进展
J Clin Med. 2021 Mar 17;10(6):1242. doi: 10.3390/jcm10061242.
2
Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.治疗药物监测在炎症性肠病的生物制剂和小分子治疗中的应用。
Medicina (Kaunas). 2024 Jan 31;60(2):250. doi: 10.3390/medicina60020250.
3
Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.英夫利昔单抗和维得利珠单抗治疗炎症性肠病的治疗药物监测。
Inflamm Bowel Dis. 2018 Sep 15;24(10):2165-2172. doi: 10.1093/ibd/izy134.
4
Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease.炎症性肠病中小分子和生物疗法的治疗药物监测进展
Curr Treat Options Gastroenterol. 2019 Mar;17(1):127-145. doi: 10.1007/s11938-019-00222-9.
5
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.炎症性肠病患者生物制剂的恰当治疗药物监测。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27.
6
Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.儿童炎症性肠病的治疗药物监测
Curr Gastroenterol Rep. 2018 Apr 5;20(5):18. doi: 10.1007/s11894-018-0623-z.
7
Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?监测炎症性肠病患者的 vedolizumab 和 ustekinumab 药物水平：炒作还是希望？
Curr Opin Pharmacol. 2020 Dec;55:17-30. doi: 10.1016/j.coph.2020.09.002. Epub 2020 Oct 9.
8
Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.新型生物制剂（vedolizumab 和 ustekinumab）和小分子药物（托法替尼）在妊娠期的安全性：综述。
Drugs. 2020 Jul;80(11):1085-1100. doi: 10.1007/s40265-020-01346-4.
9
Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).维多珠单抗和优特克单抗作为第二种生物制剂在肿瘤坏死因子拮抗剂治疗失败的炎症性肠病患者中实现目标结局的有效性（ENROLL-EX研究）
Front Pharmacol. 2023 Oct 9;14:1243080. doi: 10.3389/fphar.2023.1243080. eCollection 2023.
10
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease.炎症性肠病生物制剂治疗药物监测实用指南
J Clin Med. 2021 Oct 27;10(21):4990. doi: 10.3390/jcm10214990.
引用本文的文献
1
Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice.炎症性肠病中先进疗法的定位与排序：临床实践指南
World J Gastroenterol. 2025 Aug 7;31(29):107745. doi: 10.3748/wjg.v31.i29.107745.
2
Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab maintenance therapy for Crohn's disease patients.治疗药物监测指导下优特克单抗维持治疗对克罗恩病患者的长期疗效
Sci Rep. 2025 Jul 15;15(1):25540. doi: 10.1038/s41598-025-09802-5.
3
Mapping the Evolution of IBD Treatment: A Bibliometric Study on Biologics and Small Molecules.绘制炎症性肠病治疗的演变图谱：一项关于生物制剂和小分子的文献计量学研究
Pharmaceuticals (Basel). 2025 Feb 24;18(3):312. doi: 10.3390/ph18030312.
4
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease.在一项炎症性肠病前瞻性队列研究中，优特克单抗的药物清除率与疾病控制的相关性优于血清谷浓度。
Pharmaceutics. 2025 Feb 2;17(2):187. doi: 10.3390/pharmaceutics17020187.
5
Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice.炎症性肠病的实验室检查：基于证据的日常实践方法。
Biomedicines. 2025 Feb 17;13(2):491. doi: 10.3390/biomedicines13020491.
6
[Position paper of the Society for Paediatric Gastroenterology and Nutrition (GPGE) on the off-label use of biologics and signal inhibitors in children and adolescents with IBD that have already been approved for adults].[儿科学胃肠病学与营养学会（GPGE）关于已获批用于成人的生物制剂和信号抑制剂在儿童及青少年炎症性肠病中的超说明书使用的立场文件]
Z Gastroenterol. 2025 Mar;63(3):255-268. doi: 10.1055/a-2474-3104. Epub 2025 Feb 17.
7
Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics.维多珠单抗清除率作为炎症性肠病患者缓解的替代标志物：来自真实世界药代动力学的见解
Pharmaceutics. 2024 Dec 23;16(12):1629. doi: 10.3390/pharmaceutics16121629.
8
Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients.中度至重度克罗恩病患者血清乌司奴单抗浓度与内镜疾病活动度之间的关联
Crohns Colitis 360. 2024 Nov 29;6(4):otae071. doi: 10.1093/crocol/otae071. eCollection 2024 Oct.
9
The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study.加拿大一项真实世界研究中维多珠单抗药物浓度、炎症生物标志物与临床结局之间的关系。
J Can Assoc Gastroenterol. 2024 Mar 24;7(4):290-298. doi: 10.1093/jcag/gwae010. eCollection 2024 Aug.
10
Approach to loss of response to advanced therapies in inflammatory bowel disease.炎症性肠病对高级治疗反应丧失的处理方法。
World J Gastroenterol. 2024 Jun 14;30(22):2902-2919. doi: 10.3748/wjg.v30.i22.2902.
本文引用的文献
1
Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.乌司奴单抗静脉再诱导治疗对失应答克罗恩病患者的疗效
J Can Assoc Gastroenterol. 2022 May 26;5(5):208-213. doi: 10.1093/jcag/gwac017. eCollection 2022 Oct.
2
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.皮下注射维得利珠单抗治疗中重度活动期克罗恩病的疗效和安全性：VISIBLE 2 随机试验结果。
J Crohns Colitis. 2022 Jan 28;16(1):27-38. doi: 10.1093/ecco-jcc/jjab133.
3
Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn's Disease.三种商业检测方法测定克罗恩病患者血清乌司奴单抗浓度的比较
J Can Assoc Gastroenterol. 2020 Mar 31;4(2):73-77. doi: 10.1093/jcag/gwaa003. eCollection 2021 Apr.
4
Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?监测炎症性肠病患者的 vedolizumab 和 ustekinumab 药物水平：炒作还是希望？
Curr Opin Pharmacol. 2020 Dec;55:17-30. doi: 10.1016/j.coph.2020.09.002. Epub 2020 Oct 9.
5
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study.每四周90毫克乌司奴单抗强化治疗克罗恩病的有效性和安全性：一项多中心研究。
J Crohns Colitis. 2020 Sep 8. doi: 10.1093/ecco-jcc/jjaa177.
6
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.在接受维得利珠单抗或乌司奴单抗治疗的炎症性肠病患者中，联合治疗并未提高临床或内镜缓解率。
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1366-1376.e2. doi: 10.1016/j.cgh.2020.07.012. Epub 2020 Jul 12.
7
No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.炎症性肠病患者中，联合免疫调节剂治疗对非肿瘤坏死因子拮抗剂生物制剂疗效无益处：一项荟萃分析。
Clin Gastroenterol Hepatol. 2021 Apr;19(4):668-679.e8. doi: 10.1016/j.cgh.2020.06.071. Epub 2020 Jul 3.
8
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.JAK-STAT 通路靶向治疗炎症性肠病。
Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):323-337. doi: 10.1038/s41575-020-0273-0. Epub 2020 Mar 19.
9
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.静脉诱导治疗后乌司奴单抗的峰值浓度可识别出可能实现内镜和生化缓解的克罗恩病患者。
Clin Gastroenterol Hepatol. 2021 Jan;19(1):111-118.e10. doi: 10.1016/j.cgh.2020.02.033. Epub 2020 Feb 25.
10
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.乌司奴单抗药代动力学和在溃疡性结肠炎 3 期随机试验中的暴露反应。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2244-2255.e9. doi: 10.1016/j.cgh.2019.11.059. Epub 2019 Dec 7.
Zotero 插件